Xiaolin Wang, Sc.D.
Executive Vice President, Development
Xiaolin Wang, Sc.D. has served as our Executive Vice President, Development, since March 2021 and as our Senior Vice President, Clinical Development from March 2018 to March 2021. Xiaolin oversees clinical operations, biometrics, translational medicine, regulatory affairs, quality, nonclinical development, and clinical pharmacology, as well as program, portfolio and alliance management.
Xiaolin has over 25 years of experience in design, strategy, and execution spanning all phases of clinical development across various therapeutic areas, including solid tumors, lymphoid and myeloid malignancies, and others.
Prior to joining Revolution Medicines, Xiaolin held leadership and management positions with increasing responsibilities at Acerta Pharma (a member of the AstraZeneca Group), Geron Corporation and Genentech, Inc.
She holds a B.S. in Probability and Statistics from Peking University in China, an M.S. in Statistics from University of Washington, Seattle and a Sc.D. in Biostatistics from Harvard University.